• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
November 12, 2016 03:09 PM EST
People
Pharma

Biotech in­sid­er Rich Bag­ger is out, Gin­grich is up in lat­est reshuf­fle of Trump’s in­ner cir­cle

John Carroll

Editor & Founder

One day you’re an in­sid­er, up on top of an in­sur­rec­tionary Trump cam­paign, men­tioned on Politi­co’s short list for a promi­nent po­si­tion in the new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

more like this

  • UK gov­ern­ment pledges “bil­lions of pounds” for new re­search cen­ter in Es­sex July 17, 2025
  • Q&A with In­ter­na­tion­al AIDS So­ci­ety leader on HIV fund­ing, erad­i­cat­ing AIDS and more July 17, 2025
  • FDA hits Dae­woo Phar­ma with warn­ing let­ter over po­ten­tial­ly poi­so­nous con­t­a­m­i­nants July 17, 2025
TRENDING NOW

No­var­tis ups in­come guid­ance, ini­ti­ates $10B share buy­back

Sarep­ta adds black box warn­ing to its Duchenne treat­ment, cuts 500 work­ers

Cure­Vac CEO on BioN­Tech deal: Come to­geth­er 'rather than fight­ing each oth­er in court'

Mas­sive pro­teomics study re­veals new clues about Alzheimer’s and rekin­dles old ones

OpenEv­i­dence raised $210M in GV's 'most com­pet­i­tive' deal

BioN­Tech's strat­e­gy chief, who led deals to re­shape com­pa­ny, will leave in Sep­tem­ber

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times